SCHEMBL13248218

SCHEMBL13248218

O=C(NCCOCCI)c1ccc2nonc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.54
▸ ADORA2A P29274 1/20 0.54
▸ ADORA2B P29275 1/20 0.54
▸ ADORA1 P30542 1/20 0.54
▸ HDAC3 O15379 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ DRD3 P35462 7/20 0.45
▸ DRD2 P14416 4/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ EPHX2 P34913 1/20 0.42
▸ TAS1R3 Q7RTX0 1/20 0.42
▸ TAS1R1 Q7RTX1 1/20 0.42
▸ TAS1R2 Q8TE23 1/20 0.42
▸ HPGD P15428 1/20 0.40
▸ GRIA3 P42263 1/20 0.39
▸ GRIA4 P48058 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13248219 0.88 ADORA3 (0.55) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL13248222 0.86 ADORA3 (0.56) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL13056379 0.85 ADORA3 (0.55) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL13056382 0.82 HDAC3 (0.50) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL24012442 0.80 HPGD (0.61) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL6028978 0.78 ADORA3 (0.62) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL6028970 0.78 ADORA3 (0.62) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL13081990 0.78 ADORA3 (0.62) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL13248221 0.77 ADORA3 (0.44) ADORA3ADORA2AADORA2BADORA1HDAC3
SCHEMBL13248217 0.76 ADORA3 (0.43) ADORA3ADORA2AADORA2BADORA1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846320-B2 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. (US) 2014-09-30 — — US disclosed
US-20100184087-A1 Haptens, hapten conjugates, compositions thereof and method for their preparation and use VENTANA MEDICAL SYSTEMS, INC. 2010-07-22 — — US disclosed
US-7695929-B2 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits VENTANA MEDICAL SYSTEMS, INC. (US) 2010-04-13 — — US disclosed
US-20080268462-A1 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits VENTANA MEDICAL SYSTEMS, INC. 2008-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080268462-A1 Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits HRH4, CRBN, NCDN ADORA3 1558/4885ADORA2A 2377/4885ADORA2B 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback